Could cause temporary or reversible harm; serious harm is unlikely.
CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity above the proposed interim limit.
| Distributed by / for | Direct Rx, Dist. By Breckenridge Pharm., Inc., Berlin, CT 06037 |
| NDC | 61919-0482-30 |
| Full product label | Duloxetine D/R, 30 mg, 30 Caps, RX Only, Packaged as a) 30-count bottle NDC 61919-0482-30, b) 60-count bottle, NDC 61919-0482-60, c) 90-count bottle, NDC 61919-0482-90; Packaged & Distributed by: Direct Rx, Dist. By Breckenridge Pharm., Inc., Berlin, CT 06037, |
| Recalling firm | Direct Rx |
| Distribution | Nationwide |
| Quantity | 875 bottles |
| Recall initiated | 2025-03-07 |
| Report date | 2025-08-13 |
| Recall completed | — |
| Recall number | D-0568-2025 |
| Classification | Class II |
| FDA status | Ongoing |
| Origin on file | Dawsonville GA United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗